Send to printer »

GEN News Highlights : Oct 15, 2009

Genentech Taps Graffinity’s Fragment-Based Drug Discovery Technology

Genentech has obtained access to Graffinity Pharmaceuticals’ fragment-based drug discovery technology. Graffinity will receive technology access fees and optional payments for follow-up chemistry for the generation of novel, small molecule hits against a number of drug targets.